ClearVial BlogRegulatory intelligence and clinical workflow for peptide clinics.https://clearvial.health/blog2026-03-26T19:29:21.431ZThe GLP-1 crackdown: what 80 FDA warning letters actually saidhttps://clearvial.health/blog/glp1-warning-letters-2025-20262026-03-19Between September 2025 and March 2026, the FDA issued more than 80 warning letters related to compounded GLP-1s. Here's what violations triggered them, what legal exposure looks like now, and the six-item compliance file every clinic needs.ClearVial TeamWhat the RFK Jr. peptide announcement actually means for your clinichttps://clearvial.health/blog/rfk-peptide-announcement-20262026-03-19HHS Secretary Kennedy announced peptide reclassification on a podcast. Social media called it a done deal. Here's what the FDA's regulatory process actually requires — and what signals to watch for a real change.ClearVial TeamBPC-157 enforcement: what every prescriber needs to know in 2026https://clearvial.health/blog/bpc-157-enforcement-20262026-03-14The FDA's Category 2 determination bans BPC-157 from 503A compounding. Here's what changed, what it means for your practice, and the three things you need to do this week.ClearVial Team